A wide range of applications in both clinical and consumer markets
A wide range of applications in both clinical and consumer markets
A wide range of applications in both clinical and consumer markets
We have taken the most successful consumer diagnostic technology and adapted it for multiple markets.
Glucose monitors are the most successful consumer diagnostic product with a $15bn market. Luas Diagnostics has re-engineered the sensor used in glucose monitors and applied it to detect a wide range of analytes.
Glucose monitors are the most successful consumer diagnostic product with a $15bn market. Luas Diagnostics has re-engineered the sensor used in glucose monitors and applied it to detect a wide range of analytes.
Therapeutic Drug Monitoring (TDM) Test Market
Luas Diagnostics has a range of tests in development to support the Therapeutic Drug Monitoring Test (TDM) market.
TDM is the measurement of specific drugs in a patient’s bloodstream at selected intervals to help optimise individual dosing regimens.
TDM is mainly used for monitoring drugs with a narrow therapeutic range, drugs with variable absorption rates, medications for which target concentrations are difficult to monitor and drugs that can cause adverse effects. TDM aims to validate and optimise appropriate concentrations of difficult-to-manage medications to enable the assessment of the efficacy and safety of the medication in a variety of clinical environments.
Global Therapeutic TDM test market in 2018
Estimated market value by 2024
Compound Annual Growth Rate
3 tests in the pipeline
We are currently developing tests to monitor therapeutic drugs for bipolar disorder and COPD and a third test to assess the efficacy of anticoagulant therapy
Currently in development
Lithium
Treatment of bipolar disorder and schizophrenia
Global testing market $107m (c.10m tests p.a.)
2.4 million prescriptions each year in US
Theophylline
Respiratory disease, COPD, asthma
Global testing market $51m (c.8m tests p.a.)
Future Pipeline
PT-INR
(Prothrombin International Normalised Ratio)
Blood coagulation, liver function, anticoagulant medication monitoring
TDM Testing Pathway
Current Pathway - greater than 1 week
Patient arranges appointment with Doctor
Blood sample is taken at appointment
Sample sent to central lab for testing
Test performed at central lab
Doctor receives results and new appointment made with patient
Medication adjusted
Luas Diagnostics' Pathway - under 24 hours
Doctor
Pharmacy
Patient Choice
Home
Simple finger-stick test performed immediately
If remote, results sent via smart phone for analysis
Doctors review results on secure servers
Immediate adjustment of medication
3 Patient Choices
1) Doctor
2) Pharmacy
3) Home
Simple finger-stick test performed immediately
If remote, results sent via smart phone for analysis
If remote, results sent via smart phone for analysis
Immediate adjustment of medication
The Luas Diagnostics pathway is significantly quicker than the current traditional pathway enabling clinicians to monitor and adjust a patient’s medication within 24 hours.
Covid-19 rapid testing
The containment of the spread of Covid-19 (SARS-CoV-2) infection requires extensive testing followed by tracing of contacts of those who test positive. Reducing the turnaround time from the taking of the sample to the reporting of the result will expedite this process.
Conducting rapid testing in locations such as airports, care-homes, workplaces, clinics and drive-through testing centres and not in large laboratory settings where the turnaround time may be days, will enable results to be reported immediately, accelerating contact tracing and patient isolation, reducing further spread of infection.
Luas Diagnostics is collaborating with the Department of Biotechnology in the University of Birmingham to develop an electrochemistry-based Covid-19 antigen test using saliva rather than a nasopharyngeal swab sample. Recent studies have shown that saliva samples are more accurate than the use of nasopharyngeal swabs in the detection of the virus.
The goal is to develop a highly accurate test for Covid-19 to be used in remote settings and providing results in minutes.
Life threatening infectious diseases
Luas Diagnostics is launching an exciting range of rapid, accurate and easy to use products for life threatening infectious diseases, including Covid-19 (SARS-Cov-2) antibody and antigen tests.
The products, which are CE-IVD approved, are developed and manufactured by Chembio Diagnostic Systems Inc of Medford, New York and will be sold exclusively by Luas Diagnostics in the UK and Ireland.
